Browsing Tag
domvanalimab
2 posts
Is Arcus Biosciences (RCUS) the dark horse of cancer immunotherapy after 26.7-month survival data?
Arcus stock jumped after its domvanalimab-zimberelimab combo showed 26.7-month survival in gastric cancer. Find out what this means for its TIGIT pipeline.
October 13, 2025
Gilead Sciences invests $320m in Arcus Biosciences to accelerate cancer treatment innovations
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) have announced a significant amendment to their…
January 30, 2024